search
Back to results

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
ONO-4474 Part A1
Placebo Part A1
ONO-4474 Part A2
Placebo Part A2
ONO-4474 Part B
Placebo Part B
ONO-4474 Part C
Placebo Part C
ONO-4474 Part D
Placebo Part D
Sponsored by
Ono Pharmaceutical Co. Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy male subjects aged 18-55 years inclusive (Parts A and C); healthy male and female subjects aged 18-55 years inclusive (Part B); healthy male and female subjects aged 65 and over (Part D)
  2. Subjects with a body mass index of 18.0-30.0 kg/m2 inclusive

Exclusion Criteria:

  1. Subjects who have a clinically relevant history or presence of any clinically significant disease or disorder
  2. Current smokers or those that have smoked or used nicotine products within 6 months of the Screening visit

Sites / Locations

  • Aalborg Clinical Site
  • Nottingham Clinical SIte

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

Experimental: ONO-4474 Part A1

Experimental: ONO-4474 Placebo Part A1

Experimental: ONO-4474 Part A2

Experimental: ONO-4474 Placebo Part A2

Experimental: ONO-4474 Part B

Experimental: ONO-4474 Placebo Part B

Experimental: ONO-4474 Part C

Experimental: ONO-4474 Placebo Part C

Experimental: ONO-4474 Part D

Experimental: ONO-4474 Placebo Part D

Arm Description

Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo

Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo

Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo

Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo

Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo

Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo

NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design

NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design

Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo

Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo

Outcomes

Primary Outcome Measures

Safety and tolerability of ONO-4474 across ascending single and multiple doses using number of adverse events

Secondary Outcome Measures

Maximum plasma concentration of ONO-4474 (Cmax)
ONO-4474 Plasma Area Under the Curve from Time Zero to 24 hour after dosing (AUC24)
Time to Reach Maximum Observed Plasma concentration (Tmax) of ONO-4474
Plasma Decay half life (T1/2) of ONO-4474
Part C only - Evaluation of ONO-4474 vs. placebo on walking soreness using a Likert scale
Part C only: Assessment of pharmacology of ONO-4474 using change in pressure pain threshold after NGF injection.
Pressure algometry at site of NGF injection (anterior tibialis)

Full Information

First Posted
April 29, 2015
Last Updated
June 29, 2016
Sponsor
Ono Pharmaceutical Co. Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT02454387
Brief Title
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers
Official Title
A Double-blind, Single and Multiple Ascending Dose, Randomised, Placebo-controlled Study, in Healthy Adult and Elderly Subjects Exploring Safety, Tolerability, Pharmacokinetics of ONO-4474 and Pharmacology of ONO-4474 in NGF-hyperalgesia
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
May 2015 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
April 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ono Pharmaceutical Co. Ltd

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in healthy volunteers.
Detailed Description
A Double-blind, Multi-centre, Single Dose, Single and Multiple Ascending Dose, Four-part, Randomised, Placebo-controlled Study in Healthy Adult and Elderly Subjects Exploring the Safety, Tolerability, Pharmacokinetics of ONO-4474 in Fed and Fasted Conditions, and Pharmacology of ONO-4474 in NGF-hyperalgesia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
141 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental: ONO-4474 Part A1
Arm Type
Experimental
Arm Description
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Arm Title
Experimental: ONO-4474 Placebo Part A1
Arm Type
Placebo Comparator
Arm Description
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Arm Title
Experimental: ONO-4474 Part A2
Arm Type
Experimental
Arm Description
Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
Arm Title
Experimental: ONO-4474 Placebo Part A2
Arm Type
Placebo Comparator
Arm Description
Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
Arm Title
Experimental: ONO-4474 Part B
Arm Type
Experimental
Arm Description
Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Arm Title
Experimental: ONO-4474 Placebo Part B
Arm Type
Placebo Comparator
Arm Description
Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Arm Title
Experimental: ONO-4474 Part C
Arm Type
Experimental
Arm Description
NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
Arm Title
Experimental: ONO-4474 Placebo Part C
Arm Type
Placebo Comparator
Arm Description
NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
Arm Title
Experimental: ONO-4474 Part D
Arm Type
Experimental
Arm Description
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Arm Title
Experimental: ONO-4474 Placebo Part D
Arm Type
Placebo Comparator
Arm Description
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Intervention Type
Drug
Intervention Name(s)
ONO-4474 Part A1
Other Intervention Name(s)
ONO-4474
Intervention Description
Healthy volunteers
Intervention Type
Drug
Intervention Name(s)
Placebo Part A1
Other Intervention Name(s)
Placebo
Intervention Description
Healthy volunteers
Intervention Type
Drug
Intervention Name(s)
ONO-4474 Part A2
Other Intervention Name(s)
ONO-4474
Intervention Description
Healthy volunteers
Intervention Type
Drug
Intervention Name(s)
Placebo Part A2
Other Intervention Name(s)
Placebo
Intervention Description
Healthy volunteers
Intervention Type
Drug
Intervention Name(s)
ONO-4474 Part B
Other Intervention Name(s)
ONO-4474
Intervention Description
Healthy volunteers
Intervention Type
Drug
Intervention Name(s)
Placebo Part B
Other Intervention Name(s)
Placebo
Intervention Description
Healthy volunteers
Intervention Type
Drug
Intervention Name(s)
ONO-4474 Part C
Other Intervention Name(s)
ONO-4474
Intervention Description
Healthy volunteers
Intervention Type
Drug
Intervention Name(s)
Placebo Part C
Other Intervention Name(s)
Placebo
Intervention Description
Healthy volunteers
Intervention Type
Drug
Intervention Name(s)
ONO-4474 Part D
Other Intervention Name(s)
ONO-4474
Intervention Description
Healthy volunteers
Intervention Type
Drug
Intervention Name(s)
Placebo Part D
Other Intervention Name(s)
Placebo
Intervention Description
Healthy volunteers
Primary Outcome Measure Information:
Title
Safety and tolerability of ONO-4474 across ascending single and multiple doses using number of adverse events
Time Frame
Up to Day 28
Secondary Outcome Measure Information:
Title
Maximum plasma concentration of ONO-4474 (Cmax)
Time Frame
Day 1 and at Day 7
Title
ONO-4474 Plasma Area Under the Curve from Time Zero to 24 hour after dosing (AUC24)
Time Frame
Day 1 and at Day 7
Title
Time to Reach Maximum Observed Plasma concentration (Tmax) of ONO-4474
Time Frame
Day 1 and at Day 7
Title
Plasma Decay half life (T1/2) of ONO-4474
Time Frame
Day 1 and at Day 7
Title
Part C only - Evaluation of ONO-4474 vs. placebo on walking soreness using a Likert scale
Time Frame
3hr and 24hr after NGF injection
Title
Part C only: Assessment of pharmacology of ONO-4474 using change in pressure pain threshold after NGF injection.
Description
Pressure algometry at site of NGF injection (anterior tibialis)
Time Frame
3hr and 24hr after NGF injection

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male subjects aged 18-55 years inclusive (Parts A and C); healthy male and female subjects aged 18-55 years inclusive (Part B); healthy male and female subjects aged 65 and over (Part D) Subjects with a body mass index of 18.0-30.0 kg/m2 inclusive Exclusion Criteria: Subjects who have a clinically relevant history or presence of any clinically significant disease or disorder Current smokers or those that have smoked or used nicotine products within 6 months of the Screening visit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Drug Development Division
Organizational Affiliation
Ono Pharmaceutical Co. Ltd
Official's Role
Study Director
Facility Information:
Facility Name
Aalborg Clinical Site
City
Aalborg
Country
Denmark
Facility Name
Nottingham Clinical SIte
City
Nottingham
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers

We'll reach out to this number within 24 hrs